Cellectis SA (CLLS) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cellectis SA is showcasing its innovative strategies to improve the effectiveness of CAR T-cell therapies against solid tumors at the Society for Immunotherapy of Cancer’s Annual Meeting. By using TALEN-mediated gene editing, Cellectis aims to enhance the efficacy of these therapies while minimizing potential toxicities, offering hope for patients with challenging malignancies. This development underscores the company’s commitment to advancing cancer treatment with cutting-edge biotechnology.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.